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Recommendations to Prevent and Control Iron
Deficiency in the United States
Summary
Iron deficiency is the most common known form of nutritional deficiency. Its
prevalence is highest among young children and women of childbearing age
(particularly pregnant women). In children, iron deficiency causes developmen-
tal delays and behavioral disturbances, and in pregnant women, it increases the
risk for a preterm delivery and delivering a low-birthweight baby. In the past
three decades, increased iron intake among infants has resulted in a decline in
childhood iron-deficiency anemia in the United States. As a consequence, the
use of screening tests for anemia has become a less efficient means of detecting
iron deficiency in some populations. For women of childbearing age, iron defi-
ciency has remained prevalent.
To address the changing epidemiology of iron deficiency in the United States,
CDC staff in consultation with experts developed new recommendations for use
by primary health-care providers to prevent, detect, and treat iron deficiency.
These recommendations update the 1989 “CDC Criteria for Anemia in Children
and Childbearing-Aged Women” (MMWR 1989;38(22):400–4) and are the first
comprehensive CDC recommendations to prevent and control iron deficiency.
CDC emphasizes sound iron nutrition for infants and young children, screening
for anemia among women of childbearing age, and the importance of low-dose
iron supplementation for pregnant women.
INTRODUCTION
In the human body, iron is present in all cells and has several vital functions—as a
carrier of oxygen to the tissues from the lungs in the form of hemoglobin (Hb), as a
facilitator of oxygen use and storage in the muscles as myoglobin, as a transport me-
dium for electrons within the cells in the form of cytochromes, and as an integral part
of enzyme reactions in various tissues. Too little iron can interfere with these vital
functions and lead to morbidity and mortality.
In the United States, the prevalence of iron-deficiency anemia among children de-
clined during the 1970s in association with increased iron intake during infancy (1–3 ).
Because of this decline, the value of anemia as a predictor of iron deficiency has also
declined, thus decreasing the effectiveness of routine anemia screening among chil-
dren. In contrast, the rate of anemia among low-income women during pregnancy is
high, and no improvement has been noted since the 1970s (4 ). These findings, plus
increased knowledge about screening for iron status, raised questions about the ne-
cessity and effectiveness of existing U.S. programs to prevent and control iron
deficiency. CDC requested the Institute of Medicine to convene an expert committee to
develop recommendations for preventing, detecting, and treating iron-deficiency ane-
mia among U.S. children and U.S. women of childbearing age. The committee met
throughout 1992, and in 1993 the Institute of Medicine published the committee’s rec-
ommendations (5 ). These guidelines are not practical for all primary health-care and
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public health settings, however, because they require serum ferritin testing during
pregnancy (6 ). This testing may be appropriate in practices where women consis-
tently visit their physician throughout pregnancy, but it is less feasible when analysis
of serum ferritin concentration is unavailable or when prenatal care visits are spo-
radic. The CDC recommendations in this report—including those for pregnant
women—were developed for practical use in primary health-care and public health
settings.
Beside the Institute of Medicine (5,7 ), the American Academy of Pediatrics (8,9 ),
the U.S. Preventive Services Task Force (10 ), the American College of Obstetricians
and Gynecologists (9,11 ), the Federation of American Societies for Experimental Biol-
ogy (12 ), and the U.S. Public Health Service (13 ) have all published guidelines within
the past 9 years for health-care providers that address screening for and treatment of
iron deficiency in the United States. Preventing and controlling iron deficiency are also
addressed in Nutrition and Your Health: Dietary Guidelines for Americans (14 ).
The CDC recommendations differ from the guidelines published by the U.S. Pre-
ventive Services Task Force (10 ) in two major areas. First, the Task Force rec-
ommended screening for anemia among infants at high risk for anemia and pregnant
women only. The CDC recommends periodic screening for anemia among high-risk
populations of infants and preschool children, among pregnant women, and among
nonpregnant women of childbearing age. Second, the Task Force stated there is insuf-
ficient evidence to recommend for or against iron supplementation during pregnancy,
but the CDC recommends universal iron supplementation to meet the iron require-
ments of pregnancy. The CDC recommendations for iron supplementation during
pregnancy are similar to the guidelines issued by the American Academy of Pediatrics
and the American College of Obstetricians and Gynecologists (9 ).
This report is intended to provide guidance to primary health-care providers and
emphasizes the etiology and epidemiology of iron deficiency, the laboratory tests
used to assess iron status, and the screening for and treatment of iron deficiency at all
ages. The recommendations in this report are based on the 1993 Institute of Medicine
guidelines; the conclusions of an expert panel convened by CDC in April 1994; and
input from public health nutrition program personnel, primary health-care providers,
and experts in hematology, biochemistry, and nutrition.
National health objective 2.10 for the year 2000 is to “reduce iron deficiency to <3%
among children aged 1–4 and among women of childbearing age” (15 ). The recom-
mendations in this report for preventing and controlling iron deficiency are meant to
move the nation toward this objective.
BACKGROUND
Iron Metabolism
Total body iron averages approximately 3.8 g in men and 2.3 g in women, which is
equivalent to 50 mg/kg body weight for a 75-kg man (16,17 ) and 42 mg/kg body
weight for a 55-kg woman (18 ), respectively. When the body has sufficient iron to
meet its needs, most iron (>70%) may be classified as functional iron; the remainder is
storage or transport iron. More than 80% of functional iron in the body is found in the
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red blood cell mass as Hb, and the rest is found in myoglobin and intracellular respi-
ratory enzymes (e.g., cytochromes) (Table 1). Iron is stored primarily as ferritin, but
some is stored as hemosiderin. Iron is transported in blood by the protein transferrin.
The total amount of iron in the body is determined by intake, loss, and storage of this
mineral (16 ).
Iron Intake
Regulation of iron balance occurs mainly in the gastrointestinal tract through ab-
sorption. When the absorptive mechanism is operating normally, a person maintains
functional iron and tends to establish iron stores. The capacity of the body to absorb
iron from the diet depends on the amount of iron in the body, the rate of red blood cell
production, the amount and kind of iron in the diet, and the presence of absorption
enhancers and inhibitors in the diet.
The percentage of iron absorbed (i.e., iron bioavailability) can vary from <1% to
>50% (19 ). The main factor controlling iron absorption is the amount of iron stored in
the body. The gastrointestinal tract increases iron absorption when the body’s iron
stores are low and decreases absorption when stores are sufficient. An increased rate
of red blood cell production can also stimulate iron uptake severalfold (16,20 ).
Among adults, absorption of dietary iron averages approximately 6% for men and
13% for nonpregnant women in their childbearing years (19 ). The higher absorption
efficiency of these women reflects primarily their lower iron stores as a result of men-
struation and pregnancy. Among iron-deficient persons, iron absorption is also high
(21 ). Absorption of iron increases during pregnancy, but the amount of the increase is
not well defined (6 ); as iron stores increase postpartum, iron absorption decreases.
Iron bioavailability also depends on dietary composition. Heme iron, which is
found only in meat, poultry, and fish, is two to three times more absorbable than non-
heme iron, which is found in plant-based foods and iron-fortified foods (19,20 ). The
bioavailability of non-heme iron is strongly affected by the kind of other foods in-
gested at the same meal. Enhancers of iron absorption are heme iron (in meat,
poultry, and fish) and vitamin C; inhibitors of iron absorption include polyphenols (in
certain vegetables), tannins (in tea), phytates (in bran), and calcium (in dairy products)
(16,22 ). Vegetarian diets, by definition, are low in heme iron. However, iron bioavail-
ability in a vegeterian diet can be increased by careful planning of meals to include
TABLE 1. Normal distribution of iron-containing compounds in men (17 ) and women






Transferrin <1 <1 
Functional compounds
Hemoglobin 31 31 
Myoglobin 4 4
Respiratory enzymes 2 2
Total 50 42 
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other sources of iron and enhancers of iron absorption (14 ). In the diet of an infant,
before the introduction of solid foods, the amount of iron absorbed depends on the
amount and bioavailability of iron in breast milk or formula (8 ) (Table 2).
Iron Turnover and Loss
Red blood cell formation and destruction is responsible for most iron turnover in
the body. For example, in adult men, approximately 95% of the iron required for the
production of red blood cells is recycled from the breakdown of red blood cells and
only 5% comes from dietary sources. In contrast, an infant is estimated to derive ap-
proximately 70% of red blood cell iron from the breakdown of red blood cells and 30%
from the diet (23 ).
In adults, approximately 1 mg of iron is lost daily through feces and desquamated
mucosal and skin cells (24 ). Women of childbearing age require additional iron to
compensate for menstrual blood loss (an average of 0.3–0.5 mg daily during the child-
bearing years) (18 ) and for tissue growth during pregnancy and blood loss at delivery
and postpartum (an average of 3 mg daily over 280 days’ gestation) (25 ). In all per-
sons, a minute amount of iron is lost daily from physiological gastrointestinal blood
loss. Pathological gastrointestinal iron loss through gastrointestinal bleeding occurs
in infants and children sensitive to cow’s milk and in adults who have peptic ulcer
disease, inflammatory bowel syndrome, or bowel cancer. Hookworm infections, al-
though not common in the United States (26 ), are also associated with gastro-
intestinal blood loss and iron depletion (27 ).
Iron Stores
Iron present in the body beyond what is immediately needed for functional pur-
poses is stored as the soluble protein complex ferritin or the insoluble protein
complex hemosiderin (16,17 ). Ferritin and hemosiderin are present primarily in the
liver, bone marrow, spleen, and skeletal muscles. Small amounts of ferritin also circu-
late in the plasma. In healthy persons, most iron is stored as ferritin (an estimated 70%
in men and 80% in women) and smaller amounts are stored as hemosiderin (Table 1).
When long-term negative iron balance occurs, iron stores are depleted before iron
deficiency begins.
Men store approximately 1.0–1.4 g of body iron (17,28 ), women approximately 0.2–
0.4 g (18,28 ), and children even less (23 ). Full-term infants of normal or high
birthweight are born with high body iron (an average of 75 mg/kg body weight), to
which iron stores contribute approximately 25% (23 ). Preterm or low-birthweight in-








Nonfortified formula 1.5–4.8* ~10 0.15–0.48
Iron-fortified formula† 10.0–12.8* ~ 4 0.40–0.51
Whole cow’s milk 0.5 ~10 0.05
Breast milk 0.5 ~50 0.25
*Values are given for commonly marketed infant formulas.
†Iron-fortified formula contains ≥1.0 mg iron/100 kcal formula (8 ). Most iron-fortified formulas
contain approximately 680 kcal/L, which is equivalent to ≥6.8 mg iron/L.
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fants are born with the same ratio of total body iron to body weight, but because their
body weight is low, the amount of stored iron is low too.
Manifestations of Iron Deficiency
Iron deficiency is one of the most common nutritional deficiencies worldwide (29 )
and has several causes (Exhibit 1). Iron deficiency represents a spectrum (Table 3)
ranging from iron depletion, which causes no physiological impairments, to iron-defi-
ciency anemia, which affects the functioning of several organ systems. In iron
depletion, the amount of stored iron (e.g., as measured by serum ferritin concentra-
tion) is reduced but the amount of functional iron may not be affected (30,31 ). Persons
who have iron depletion have no iron stores to mobilize if the body requires more
iron. In iron-deficient erythropoiesis, stored iron is depleted and transport iron (e.g., as
measured by transferrin saturation) is reduced further; the amount of iron absorbed is
not sufficient to replace the amount lost or to provide the amount needed for growth
and function. In this stage, the shortage of iron limits red blood cell production and
results in increased erthryocyte protoporphyrin concentration. In iron-deficiency ane-
mia, the most severe form of iron deficiency, the shortage of iron leads to
underproduction of iron-containing functional compounds, including Hb. The red
blood cells of persons who have iron-deficiency anemia are microcytic and hypo-
chromic (30,31 ).
In infants (persons aged 0–12 months) and preschool children (persons aged 1–5
years), iron-deficiency anemia results in developmental delays and behavioral distur-
bances (e.g., decreased motor activity, social interaction, and attention to tasks)
(32,33). These developmental delays may persist past school age (i.e., 5 years) if the
iron deficiency is not fully reversed (32–34 ). In these studies of development and be-
havior, iron-deficiency anemia was defined as a Hb concentration of ≤10.0 g/dL or
≤10.5 g/dL; further study is needed to determine the effects of mild iron-deficiency
anemia (for example, a Hb concentration of >10.0 g/dL but <11.0 g/dL in children aged
1–<2 years) on infant and child development and behavior. Iron-deficiency anemia
also contributes to lead poisoning in children by increasing the gastrointestinal tract’s
ability to absorb heavy metals, including lead (35 ). Iron-deficiency anemia is associ-
ated with conditions that may independently affect infant and child development (e.g.,
low birthweight, generalized undernutrition, poverty, and high blood level of lead) that
need to be taken into account when interventions addressing iron-deficiency anemia
are developed and evaluated (34 ).
EXHIBIT 1. Causes of iron deficiency
Increased iron requirements Inadequate iron absorption
Blood loss Diet low in bioavailable iron
  Menstruation Impaired absorption
  Gastrointestinal tract   Intestinal malabsorption
     Food sensitivity   Gastric surgery
     Hookworms   Hypochlorhydria
  Genitourinary tract
  Respiratory tract
  Blood donation
Growth
Pregnancy
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In adults (persons aged ≥18 years), iron-deficiency anemia among laborers (e.g.,
tea pickers, latex tappers, and cotton mill workers) in the developing world impairs
work capacity; the impairment appears to be at least partially reversible with iron
treatment (36,37 ). It is not known whether iron-deficiency anemia affects the capacity
to perform less physically demanding labor that is dependent on sustained cognitive
or coordinated motor function (37 ).
Among pregnant women, iron-deficiency anemia during the first two trimesters of
pregnancy is associated with a twofold increased risk for preterm delivery and a three-
fold increased risk for delivering a low-birthweight baby (38 ). Evidence from
randomized control trials indicates that iron supplementation decreases the incidence
of iron-deficiency anemia during pregnancy (10,39–42 ), but trials of the effect of uni-
versal iron supplementation during pregnancy on adverse maternal and infant
outcomes are inconclusive (10,43,44 ).
Risk for and Prevalence of Iron Deficiency in the United States
A rapid rate of growth coincident with frequently inadequate intake of dietary iron
places children aged <24 months, particularly those aged 9–18 months, at the highest
risk of any age group for iron deficiency (3 ). The iron stores of full-term infants can
meet an infant’s iron requirements until ages 4–6 months, and iron-deficiency anemia
generally does not occur until approximately age 9 months. Compared with full-term
infants of normal or high birthweight, preterm and low-birthweight infants are born
with lower iron stores and grow faster during infancy; consequently, their iron stores
are often depleted by ages 2–3 months (5,23 ) and they are at greater risk for iron
deficiency than are full-term infants of normal or high birthweight. Data from the third
National Health and Nutrition Examination Survey (NHANES III), which was con-
ducted during 1988–1994, indicated that 9% of children aged 12–36 months in the
United States had iron deficiency (on the basis of two of three abnormal values for
erythrocyte protoporphyrin concentration, serum ferritin concentration, and transfer-
rin saturation) and that 3% also had iron-deficiency anemia (Table 4). The prevalence
of iron deficiency is higher among children living at or below the poverty level than
among those living above the poverty level and higher among black or Mexican-
American children than among white children (45 ).
Evidence from the Continuing Survey of Food Intakes by Individuals (CSFII), which
was conducted during 1994–1996, suggests that most infants meet the recommended
dietary allowance for iron through diet (Table 5; these data exclude breast-fed infants).
However, the evidence also suggests that more than half of children aged 1–2 years
TABLE 3. Spectrum of body iron content (17,30,31 )
Iron status Stored iron Transport iron Functional iron
Iron-deficiency anemia Low Low Low
Iron-deficient erythropoiesis Low Low Normal
Iron depletion Low Normal Normal
Normal Normal Normal Normal
Iron overload High High Normal
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may not be meeting the recommended dietary allowance for iron through their diet
(Table 5; these data do not include iron intake from supplemental iron).
An infant’s diet is a reasonable predictor of iron status in late infancy and early
childhood (23,48 ). For example, approximately 20%–40% of infants fed only non-iron-
fortified formula or whole cow’s milk and 15%–25% of breast-fed infants are at risk for
iron deficiency by ages 9–12 months (23,48 ). Infants fed mainly iron-fortified formula
(≥1.0 mg iron/100 kcal formula) (8 ) are not likely to have iron deficiency at age 9
months (48 ). Another study has documented that intake of iron-fortified cereal pro-
tects against iron deficiency: among exclusively breast-fed infants who were fed
cereal starting at age 4 months, 3% of infants who were randomized to receive iron-
fortified cereal compared with 15% of infants who were randomized to receive
non-iron-fortified cereal had iron-deficiency anemia at age 8 months (49 ). The effect
of prolonged exclusive breast feeding on iron status is not well understood. One non-
randomized study with a small cohort suggested that exclusive breast feeding for >7
months is protective against iron deficiency compared with breast feeding plus the
introduction of non-iron-fortified foods at age ≤7 months (50 ); infants weaned to iron-
fortified foods were not included in this study.
Early introduction (i.e., before age 1 year) of whole cow’s milk and consumption of
>24 oz of whole cow’s milk daily after the 1st year of life are risk factors for iron defi-
ciency because this milk has little iron, may replace foods with higher iron content,
and may cause occult gastrointestinal bleeding (8,48,51,52 ). Because goat’s milk and
cow’s milk have similar compositions (53,54 ), infants fed goat’s milk are likely to have
the same risk for developing iron deficiency as do infants fed cow’s milk. Of all milks
and formulas, breast milk has the highest percentage of bioavailable iron, and breast
milk and iron-fortified formulas provide sufficient iron to meet an infant’s needs (55 ).
Iron-fortified formulas are readily available, do not cost much more than non-iron-for-
TABLE 4. Prevalence (%) of iron deficiency and iron-deficiency anemia, United States,
third National Health and Nutrition Examination Survey, 1988–1994 (45 )
Sex and age (years) Iron deficiency Iron-deficiency anemia
Both sexes
1–2 9  3*
3–5 3 <1 
6–11 2 <1 
Nonpregnant females
12–15 9  2*
16–19 11*  3*
20–49 11  5*
50–69 5 2
≥70  7*  2*
Males
12–15 1 <1 
16–19 <1 <1 
20–49 <1 <1 
50–69 2 1
≥70 4 2
*Prevalence in nonblacks is 1 percentage point lower than prevalence in all races.
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tified formulas, and have few proven side effects except for darker stools (56,57 ). Con-
trolled trials and observational studies have indicated that iron-fortified formula
causes no more gastrointestinal distress than does non-iron-fortified formula (56–58 ),
and there is little medical indication for non-iron-fortified formula (59 ).
After age 24 months, when the growth rate of children slows and the diet becomes
more diversified, the risk for iron deficiency drops (28,45,47 ). In children aged >36
months, dietary iron and iron status are usually adequate (45,47 ). For these older chil-
dren, risks for iron deficiency include limited access to food (e.g., because of low
family income (45 ) or because of migrant or refugee status), a low-iron or other spe-
cialized diet, and medical conditions that affect iron status (e.g., inflammatory or
bleeding disorders) (3 ).
During adolescence (ages 12–<18 years), iron requirements (46 ) and hence the risk
for iron deficiency increase because of rapid growth (60,61 ). Among boys, the risk
subsides after the peak pubertal growth period. Among girls and women, however,
menstruation increases the risk for iron deficiency throughout the childbearing years.
An important risk factor for iron-deficiency anemia among nonpregnant women of
TABLE 5. 1989 Recommended dietary allowance (RDA) for iron and the proportion of
Americans having diets meeting 100% of the RDA for iron, 1994–1996
Sex and age (years) RDA (mg/day)*
Proportion of Americans
meeting 100% of the
1989 RDA for iron† (%)
Both sexes





















*National Research Council (46 ). The age groups designated by the council are slightly different
from those presented in this table.
†Two-day average dietary intakes, from the U.S. Department of Agriculture Continuing Survey
of Food Intakes by Individuals, 1994–1996 (47 ).
§Excludes breast-fed infants.
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childbearing age is heavy menstrual blood loss (≥80 mL/month) (18 ), which affects an
estimated 10% of these women in the United States (17,18 ). Other risk factors include
use of an intrauterine device (which is associated with increased menstrual blood
loss), high parity, previous diagnosis of iron-deficiency anemia, and low iron intake
(45,60 ). Use of oral contraceptives is associated with decreased risk for iron defi-
ciency (18,62 ).
Data from CSFII suggest that only one fourth of adolescent girls and women of
childbearing age (12–49 years) meet the recommended dietary allowance for iron
through diet (Table 5). Indeed, data from the complete NHANES III indicated that 11%
of nonpregnant women aged 16–49 years had iron deficiency and that 3%–5% also
had iron-deficiency anemia (Table 4).
Among pregnant women, expansion of blood volume by approximately 35% and
growth of the fetus, placenta, and other maternal tissues increase the demand for iron
threefold in the second and third trimesters to approximately 5.0 mg iron/day (18,46 ).
Although menstruation ceases and iron absorption increases during pregnancy, most
pregnant women who do not take iron supplements to meet increased iron require-
ments during pregnancy cannot maintain adequate iron stores, particularly during the
second and third trimesters (63 ). After delivery, the iron in the fetus and placenta is
lost to the woman, but some of the iron in the expanded blood volume may be re-
turned to the woman’s iron stores (18 ).
The prevalence of anemia in low-income, pregnant women enrolled in public
health programs in the United States has remained fairly stable since 1979 (4 ). In
1993, the prevalence of anemia among these women was 9%, 14%, and 37% in the
first, second, and third trimesters, respectively (4 ). Comparable data for the U.S.
population of all pregnant women are unavailable. The low dietary intake of iron
among U.S. women of childbearing age (47 ), the high prevalence of iron deficiency
and iron-deficiency anemia among these women (45 ), and the increased demand for
iron during pregnancy (18,46 ) suggest that anemia during pregnancy may extend be-
yond low-income women.
Published data on iron supplement use by a representative sample of pregnant
U.S. women are limited. In the 1988 National Maternal and Infant Health Survey of a
nationally representative sample of U.S. women who delivered a child in that year,
83% of respondents reported that they took supplements with multiple vitamins and
minerals ≥3 days/week for 3 months after they found out they were pregnant (64 ).
Significantly smaller percentages of black women; Eskimo, Aleut, or American Indian
women; women aged <20 years; and women having less than a high school education
reported taking these supplements. In this survey, self-reported use of supplementa-
tion was within the range (55%–95%) found in a review of studies using objective
measures to estimate adherence (e.g., pill counts and serum ferritin concentration)
(65) . The survey results suggest that the groups of women at high risk for iron defi-
ciency during nonpregnancy are less likely to take supplements with multiple vitamins
and minerals during pregnancy. This survey did not question respondents about
changes in supplement use during pregnancy or what dose of iron supplements was
consumed.
In the United States, the main reasons for lack of a recommended iron supplemen-
tation regimen during pregnancy may include lack of health-care provider and patient
perceptions that iron supplements improve maternal and infant outcomes (65 ), com-
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plicated dose schedules (5,65 ), and uncomfortable side effects (e.g., constipation,
nausea, and vomiting) (66,67 ). Low-dose supplementation regimens that meet preg-
nancy requirements (i.e., 30 mg iron/day) (46 ) and reduce unwanted side effects are
as effective as higher dose regimens (i.e., 60 or 120 mg iron/day) in preventing iron-
deficiency anemia (66 ). Simplified dose schedules (e.g., 1 dose/day) may also im-
prove compliance (65 ). Methods to improve compliance among pregnant women at
high risk for iron deficiency require further study.
Among men (males aged ≥18 years) and postmenopausal women in the United
States, iron-deficiency anemia is uncommon. Data from NHANES III indicated that
≤2% of men aged ≥20 years and 2% of women aged ≥50 years had iron-deficiency
anemia (Table 4). Data from CFSII indicate that most men and most women aged ≥50
years meet the recommended dietary allowance for iron through diet (Table 5). In a
study of adults having iron-deficiency anemia, 62% had clinical evidence of gastroin-
testinal bleeding as a result of lesions (e.g., ulcers and tumors) (68 ). In NHANES I,
which was conducted during 1971–1975, about two thirds of anemia cases among
men and postmenopausal women were attributable to chronic disease or inflamma-
tory conditions (69 ). The findings of these studies suggest that, among these
populations, the primary causes of anemia are chronic disease and inflammatory con-
ditions and that low iron intake should not be assumed to be the cause of the anemia.
TESTS USED TO ASSESS IRON STATUS
Iron status can be assessed through several laboratory tests. Because each test
assesses a different aspect of iron metabolism, results of one test may not always
agree with results of other tests. Hematological tests based on characteristics of red
blood cells (i.e., Hb concentration, hematocrit, mean cell volume, and red blood cell
distribution width) are generally more available and less expensive than are biochemi-
cal tests. Biochemical tests (i.e., erythrocyte protoporphyrin concentration, serum
ferritin concentration, and transferrin saturation), however, detect earlier changes in
iron status.
Although all of these tests can be used to assess iron status, no single test is ac-
cepted for diagnosing iron deficiency (70 ). Detecting iron deficiency in a clinical or
field setting is more complex than is generally believed.
Lack of standardization among the tests and a paucity of laboratory proficiency
testing limit comparison of results between laboratories (71 ). Laboratory proficiency
testing is currently available for measuring Hb concentration, hematocrit, red blood
cell count, serum ferritin concentration, and serum iron concentration; provisional
proficiency testing was added in 1997 for total iron-binding capacity in the College of
American Pathologists survey and was added to the American Association of Bioana-
lysts survey in 1998. As of April 1998, three states (New York, Pennsylvania, and
Wisconsin) had proficiency testing programs for erthrocyte protoporphryin concen-
tration. Regardless of whether test standardization and proficiency testing become
routine, better understanding among health-care providers about the strengths and
limitations of each test is necessary to improve screening for and diagnosis of iron-
deficiency anemia, especially because the results from all of these tests can be af-
fected by factors other than iron status.
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Only the most common indicators of iron deficiency are described in this section.
Other indicators of iron deficiency (e.g., unbound iron-binding capacity and the con-
centrations of transferrin receptor, serum transferrin, and holo-ferritin) are less often
used or are under development.
Hb Concentration and Hematocrit
Because of their low cost and the ease and rapidity in performing them, the tests
most commonly used to screen for iron deficiency are Hb concentration and hema-
tocrit (Hct). These measures reflect the amount of functional iron in the body. The
concentration of the iron-containing protein Hb in circulating red blood cells is the
more direct and sensitive measure. Hct indicates the proportion of whole blood occu-
pied by the red blood cells; it falls only after the Hb concentration falls. Because
changes in Hb concentration and Hct occur only at the late stages of iron deficiency,
both tests are late indicators of iron deficiency; nevertheless, these tests are essential
for determining iron-deficiency anemia.
Because iron deficiency is such a common cause of childhood anemia, the terms
anemia, iron deficiency, and iron-deficiency anemia are often used interchangeably
(3 ) . The only cases of anemia that can be classified as iron-deficiency anemia, how-
ever, are those with additional evidence of iron deficiency. The concept of a close
association between anemia and iron deficiency is closest to correct when the preva-
lence of iron deficiency is high. In the United States, the prevalence and severity of
anemia have declined in recent years; hence, the proportion of anemia due to causes
other than iron deficiency has increased substantially. As a consequence, the effec-
tiveness of anemia screening for iron deficiency has decreased in the United States.
Iron deficiency may be defined as absent bone marrow iron stores (as described on
bone marrow iron smears), an increase in Hb concentration of >1.0 g/dL after iron
treatment, or abnormal values on certain other biochemical tests (17 ). The recent rec-
ognition that iron deficiency seems to have general and potentially serious negative
effects (32–34 ) has made identifying persons having iron deficiency as important as
identifying persons having iron-deficiency anemia.
The case definition of anemia recommended in this report is <5th percentile of the
distribution of Hb concentration or Hct in a healthy reference population and is based
on age, sex, and (among pregnant women) stage of pregnancy (45,72 ). This case defi-
nition for anemia was shown to correctly identify 37% of women of childbearing age
and 25% of children aged 1–5 years who were iron deficient (defined as two of three
positive test results [i.e., low mean cell volume, high erythrocyte protoporphyrin, or
low transferrin saturation]) (sensitivity) and to correctly classify 93% of women of
childbearing age and 92% of children aged 1–5 years as not having iron deficiency
(specificity) (73 ). Lowering the Hb concentration or Hct cut-off would result in identi-
fying fewer people who have anemia due to causes other than iron deficiency (false
positives) but also in overlooking more people with iron deficiency (true positives)
(74) .
The distributions of Hb concentration and Hct and thus the cutoff values for anemia
differ between children, men, nonpregnant women, and pregnant women and by age
or weeks of gestation (Table 6). The distributions also differ by altitude, smoking
status, and race.
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Among pregnant women, Hb concentration and Hct decline during the first and
second trimesters because of an expanding blood volume (18,39–42 ). Among preg-
nant women who do not take iron supplements, Hb concentration and Hct remain low
in the third trimester, and among pregnant women who have adequate iron intake, Hb
concentration and Hct gradually rise during the third trimester toward the prepreg-
nancy levels (39,40 ). Because adequate data are lacking in the United States, the
cutoff values for anemia are based on clinical studies of European women who had
taken iron supplementation during pregnancy (39–42,72 ). For pregnant women, a test
TABLE 6. Maximum hemoglobin concentration and hematocrit values for anemia*
(45,72 )
Hemoglobin
concentration (<g/dL) Hematocrit (<%)

















 12 11.0 33.0
 16 10.6 32.0
 20 10.5 32.0
 24 10.5 32.0
 28 10.7 32.0
 32 11.0 33.0
 36 11.4 34.0
 40 11.9 36.0
Trimester
 First 11.0 33.0
 Second 10.5 32.0
 Third 11.0 33.0
*Age- and sex-specific cutoff values for anemia are based on the 5th percentile from the third
National Health and Nutrition Examination Survey (NHANES III), which excluded persons who
had a high likelihood of iron deficiency by using the same methods described by Looker et
al. (45 ). Maximum values for anemia during pregnancy are based on values from pregnant
women who had adequate iron supplementation (39–42,72 ). 
† Although no data are available from NHANES III to determine the maximum hemoglobin
concentration and hematocrit values for anemia among infants, the values listed for children
aged 1–<2 years can be used for infants aged 6–12 months.
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result >3 standard deviations (SD) higher than the mean of the reference population
(i.e., a Hb concentration of >15.0 g/dL or a Hct of >45.0%), particularly in the second
trimester, likely indicates poor blood volume expansion (72 ). High Hb concentration
or Hct has been associated with hypertension and poor pregnancy outcomes (e.g.,
fetal growth retardation, fetal death, preterm delivery, and low birthweight) (75–78 ).
In one study, women who had a Hct of ≥43% at 26–30 weeks’ gestation had more than
a twofold increased risk for preterm delivery and a fourfold increased risk for deliver-
ing a child having fetal growth retardation than did women who had a Hct of 33%–36%
(76 ). Hence, a high Hb concentration or Hct in the second or third trimester of preg-
nancy should not be considered an indicator of desirable iron status.
Long-term residency at high altitude (≥3,000 ft) (79 ) and cigarette smoking (80 )
cause a generalized upward shift in Hb concentration and Hct (Table 7). The effective-
ness of screening for anemia is lowered if the cutoff values are not adjusted for these
factors (72,79,80 ). Adjustment allows the positive predictive value of anemia screen-
ing to be comparable between those who reside near sea-level and those who live at
high altitude and between smokers and nonsmokers (72 ).
In the United States, the distribution of Hb concentration values is similar among
whites and Asian Americans (81 ), and the distribution of Hct values is similar among
whites and American Indians (82 ). The distributions are lower among blacks than
whites, however, even after adjustment for income (83,84 ). These different distribu-
tions are not caused by a difference in iron status indicators (e.g., iron intake, serum
ferritin concentration, or transferrin saturation); thus, applying the same criteria for
anemia to all races results in a higher rate of false-positive cases of iron deficiency for
blacks (84 ). For example, in the United States during 1976–1980, 28% of nonpregnant
black women but only 5% of nonpregnant white women had a Hb concentration of <12
g/dL and, according to the anemia criteria, would be classified as iron deficient, even
though other tests for iron status suggested these women were not iron deficient
(84 ) . For this reason, the Institute of Medicine recommends lowering Hb concentra-
tion and Hct cutoff values for black children aged <5 years by 0.4 g/dL and 1%,
TABLE 7. Adjustment of maximum hemoglobin concentration and hematocrit values
for anemia (72,79,80 )
Hemoglobin











0.5–<1.0 pack per day +0.3 +1.0
1.0–<2.0 packs per day +0.5 +1.5
≥2.0 packs per day +0.7 +2.0
All smokers +0.3 +1.0
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respectively, and for black adults by 0.8 g/dL and 2%, respectively (5 ). Because the
reason for this disparity in distributions by race has not been determined, the recom-
mendations in this report do not provide race-specific cutoff values for anemia.
Regardless, health-care providers should be aware of the possible difference in the
positive predictive value of anemia screening for iron deficiency among blacks and
whites and consider using other iron status tests (e.g., serum ferritin concentration
and transferrin saturation) for their black patients.
Accurate, low-cost, clinic-based instruments have been developed for measuring
Hb concentration and Hct by using capillary or venous blood (85,86 ). Small diurnal
variations are seen in Hb concentration and Hct measurements, but these variations
are neither biologically nor statistically significant (87,88 ). A potential source of error
of using capillary blood to estimate Hb concentration and Hct in screening is improper
sampling technique. For example, excessive squeezing (i.e., “milking”) of the finger
contaminates the blood with tissue fluid, leading to false low readings (89 ). Confirma-
tion of a low reading is recommended by obtaining a second capillary blood sample
from the finger or by venipuncture.
Although measures of Hb concentration and Hct cannot be used to determine the
cause of anemia, a diagnosis of iron-deficiency anemia can be made if Hb concentra-
tion or Hct increases after a course of therapeutic iron supplementation (23,51 ).
Alternatively, other laboratory tests (e.g., mean cell volume, red blood cell distribution
width, and serum ferritin concentration) can be used to differentiate iron-deficiency
anemia from anemia due to other causes.
In the United States in recent years, the usefulness of anemia screening as an indi-
cator of iron deficiency has become more limited, particularly for children. Studies
using transferrin saturation (a more sensitive test for iron deficiency) have docu-
mented that iron deficiency in most subpopulations of children has declined such that
screening by Hb concentration no longer efficiently predicts iron deficiency
(3,45,51,90 ) . Data from NHANES II, which was conducted during 1976–1980, indicated
that <50% of children aged 1–5 years and women in their childbearing years who had
anemia (as defined by Hb concentration <5th percentile) were iron deficient (i.e., had
at least two of the following: low mean cell volume, high erythrocyte protoporphyrin
concentration, or low transferrin saturation) (70,73,83 ). Causes of anemia other than
iron deficiency include other nutritional deficiencies (e.g., folate or vitamin B12 defi-
ciency), hereditary defects in red blood cell production (e.g., thalassemia major and
sickle cell disease), recent or current infection, and chronic inflammation (91 ). The
current pattern of iron-deficiency anemia in the United States (28,45 ) indicates that
selective anemia screening of children at known risk for iron deficiency or additional
measurement of indicators of iron deficiency (e.g., erythrocyte protoporphyrin con-
centration and serum ferritin concentration) to increase the positive predictive value
of screening are now suitable approaches to assessing iron deficiency among most
U.S. children (3,73 ). The costs and feasibility of screening using additional indicators
of iron deficiency may preclude the routine use of these indicators.
Mean Cell Volume
Mean cell volume (MCV), the average volume of red blood cells, is measured in
femtoliters (10-15 liters). This value can be calculated as the ratio of Hct to red blood
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cell count or measured directly using an electronic counter. MCV is highest at birth,
decreases during the first 6 months of life, then gradually increases during childhood
to adult levels (23,51 ). A low MCV corresponds with the 5th percentile for age for the
reference population in NHANES III (28 ).
Some anemias, including iron-deficiency anemia, result in microcytic red blood
cells; a low MCV thus indicates microcytic anemia (Table 8). If cases of lead poisoning
and the anemias of infection, chronic inflammatory disease, and thalassemia minor
can be excluded, a low MCV serves as a specific index for iron-deficiency anemia
(28,87,94,95 ).
Red Blood Cell Distribution Width
Red blood cell distribution width (RDW) is calculated by dividing the SD of red
blood cell volume by MCV and multiplying by 100 to express the result as a percent-
age:
RDW (%) = [SD of red blood cell volume (fL)/MCV (fL)] × 100
A high RDW is generally set at >14.0%, which corresponds to the 95th percentile of
RDW for the reference population in NHANES III (20 ). The RDW value obtained de-
pends on the instrument used (51,95 ).
TABLE 8. Cutoff values for laboratory tests for iron deficiency
Test Cutoff value    Reference
Hemoglobin
concentration
See Table 6 for cutoffs for anemia Looker et al. (45 ),
CDC (72 )
Hematocrit See Table 6 for cutoffs for anemia Looker et al. (45 ),
CDC (72 )
Mean cell volume Cutoffs for microcytic anemia at age:
1–2 years:     <77 fL
3–5 years:     <79 fL
6–11 years:    <80 fL
12–15 years:   <82 fL
>15 years:     <85 fL
Dallman et al. (28 )
Red blood cell
distribution width
Cutoff for iron-deficiency anemia*:
>14.0%





Cutoffs for iron deficiency:
Adults:  >30 µg/dL of whole blood or
      >70 µg/dL of red blood cells
Children aged 1–2 years:
      >80 µg/dL of red blood cells




Cutoff for iron deficiency in persons
aged >6 months: ≤15 µg/L
Hallberg et al. (93 )
Transferrin saturation Cutoff for iron deficiency: <16% Dallman et al. (23 ),
Pilch and Senti (90 )
*The cutoff is instrument specific and may not apply in all laboratories.
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An RDW measurement often follows an MCV test to help determine the cause of a
low MCV. For example, iron-deficiency anemia usually causes greater variation in red
blood cell size than does thalassemia minor (96 ). Thus, a low MCV and an RDW of
>14.0% indicates iron-deficiency anemia, whereas a low MCV and an RDW ≤14.0%
indicates thalassemia minor (51 ).
Erythrocyte Protoporphyrin Concentration
Erythrocyte protoporphyrin is the immediate precursor of Hb. The concentration of
erythrocyte protoporphyrin in blood increases when insufficient iron is available for
Hb production. A concentration of >30 µg/dL of whole blood or >70 µg/dL of red blood
cells among adults and a concentration of >80 µg/dL of red blood cells among children
aged 1–2 years indicates iron deficiency (28,45,91 ). The normal range of erythrocyte
protoporphyrin concentration is higher for children aged 1–2 years than for adults, but
no consensus exists on the normal range for infants (28,90 ). The sensitivity of free
erythrocyte protoporphyrin to iron deficiency (as determined by response to iron ther-
apy) in children and adolescents aged 6 months–17 years is 42%, and the estimated
specificity is 61% (74 ).
Infection, inflammation, and lead poisoning as well as iron deficiency can elevate
erythrocyte protoporphyrin concentration (23,92 ). This measure of iron status has
several advantages and disadvantages relative to other laboratory measures. For ex-
ample, the day-to-day variation within persons for erythrocyte protoporphyrin
concentration is less than that for serum iron concentration and transferrin saturation
(87 ). A high erythrocyte protoporphyrin concentration is an earlier indicator of iron-
deficient erythropoiesis than is anemia, but it is not as early an indicator of low iron
stores as is low serum ferritin concentration (30 ). Inexpensive, clinic-based methods
have been developed for measuring erythrocyte protoporphyrin concentration, but
these methods can be less reliable than laboratory methods (92 ).
Serum Ferritin Concentration
Nearly all ferritin in the body is intracellular; a small amount circulates in the
plasma. Under normal conditions, a direct relationship exists between serum ferritin
concentration and the amount of iron stored in the body (97 ), such that 1 µg/L of
serum ferritin concentration is equivalent to approximately 10 mg of stored iron (98 ).
In the United States, the average serum ferritin concentration is 135 µg/L for men (28),
43 µg/L for women (28 ), and approximately 30 µg/L for children aged 6–24 months
(23 ) .
Serum ferritin concentration is an early indicator of the status of iron stores and is
the most specific indicator available of depleted iron stores, especially when used in
conjunction with other tests to assess iron status. For example, among women who
test positive for anemia on the basis of Hb concentration or Hct, a serum ferritin con-
centration of ≤15 µg/L confirms iron deficiency and a serum ferritin concentration of
>15 µg/L suggests that iron deficiency is not the cause of the anemia (93 ). Among
women of childbearing age, the sensitivity of low serum ferritin concentration (≤15
µg/L) for iron deficiency as defined by no stainable bone marrow iron is 75%, and the
specificity is 98%; when low serum ferritin concentration is set at <12 µg/L, the sensi-
tivity for iron deficiency is 61% and the specificity is 100% (93 ). Although low serum
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ferritin concentration is an early indicator of low iron stores, it has been questioned
whether a normal concentration measured during the first or second trimester of
pregnancy can predict adequate iron status later in pregnancy (6 ).
The cost of assessing serum ferritin concentration and the unavailability of clinic-
based measurement methods hamper the use of this measurement in screening for
iron deficiency. In the past, methodological problems have hindered the comparability
of measurements taken in different laboratories (87 ), but this problem may be re-
duced by proficiency testing and standardized methods. Factors other than the level of
stored iron can result in large within-individual variation in serum ferritin concentra-
tion (99 ). For example, because serum ferritin is an acute-phase reactant, chronic
infection, inflammation, or diseases that cause tissue and organ damage (e.g., hepati-
tis, cirrhosis, neoplasia, or arthritis) can raise its concentration independent of iron
status (97 ). This elevation can mask depleted iron stores.
Transferrin Saturation
Transferrin saturation indicates the extent to which transferrin has vacant iron-
binding sites (e.g., a low transferrin saturation indicates a high proportion of vacant
iron-binding sites). Saturation is highest in neonates, decreases by age 4 months, and
increases throughout childhood and adolescence until adulthood (23,28 ). Transferrin
saturation is based on two laboratory measures, serum iron concentration and total
iron-binding capacity (TIBC). Transferrin saturation is calculated by dividing serum
iron concentration by TIBC and multiplying by 100 to express the result as a percent-
age:
Transferrin saturation (%) = [serum iron concentration (µg/dL)/TIBC (µg/dL)] × 100
Serum iron concentration is a measure of the total amount of iron in the serum and
is often provided with results from other routine tests evaluated by automated, labo-
ratory chemistry panels. Many factors can affect the results of this test. For example,
the concentration of serum iron increases after each meal (71 ), infections and inflam-
mations can decrease the concentration (69 ), and diurnal variation causes the
concentration to rise in the morning and fall at night (100 ). The day-to-day variation
of serum iron concentration within individuals is greater than that for Hb concentra-
tion and Hct (88,101 ).
TIBC is a measure of the iron-binding capacity within the serum and reflects the
availability of iron-binding sites on transferrin (94 ). Thus, TIBC increases when serum
iron concentration (and stored iron) is low and decreases when serum iron concentra-
tion (and stored iron) is high. Factors other than iron status can affect results from this
test. For example, inflammation, chronic infection, malignancies, liver disease, neph-
rotic syndrome, and malnutrition can lower TIBC readings, and oral contraceptive use
and pregnancy can raise the readings (87,102 ). Nevertheless, the day-to-day variation
is less than that for serum iron concentration (87,101 ). TIBC is less sensitive to iron
deficiency than is serum ferritin concentration, because changes in TIBC occur after
iron stores are depleted (17,31,94 ).
A transferrin saturation of <16% among adults is often used to confirm iron defi-
ciency (93 ). Among nonpregnant women of childbearing age, the sensitivity of low
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transferrin saturation (<16%) for iron deficiency as defined by no stainable bone mar-
row iron is 20%, and the specificity is 93% (93 ).
The factors that affect serum iron concentration and TIBC, such as iron status, diur-
nal variation (87,103 ), and day-to-day variation within persons (101 ), can affect the
measured transferrin saturation as well. The diurnal varation is larger for transferrin
saturation than it is for Hb concentration or Hct (87,103 ). Transferrin saturation is an
indicator of iron-deficient erythropoiesis rather than iron depletion; hence, it is less
sensitive to changes in iron stores than is serum ferritin concentration (30,31 ). The
cost of assessing transferrin saturation and the unavailability of simple, clinic-based
methods for measuring transferrin saturation hinder the use of this test in screening
for iron deficiency.
JUSTIFICATION FOR RECOMMENDATIONS
These recommendations are intended to guide primary health-care providers in
preventing and controlling iron deficiency in infants, preschool children, and women
of childbearing age (especially pregnant women). Both primary prevention through
appropriate dietary intake and secondary prevention through detecting and treating
iron-deficiency anemia are discussed.
Primary Prevention
Primary prevention of iron deficiency means ensuring an adequate intake of iron. A
reliable source of dietary iron is essential for every infant and child’s growth and de-
velopment, because a rapid rate of growth and low dietary iron may predispose an
infant to exhaustion of iron stores by ages 4–6 months (23 ). Primary prevention of
iron deficiency is most important for children aged <2 years, because among all age
groups they are at the greatest risk for iron deficiency caused by inadequate intake of
iron (28,45,47,48,91 ). The adequacy of the iron content of an infant’s diet is a major
determinant of the iron status of the infant as a young child, as indicated by declines
in the prevalence of iron-deficiency anemia that correspond with improvements in
infant feeding practices (1–3 ). In infants and young children, iron deficiency may re-
sult in developmental and behavioral disturbances (33,34 ).
The evidence for the effectiveness of primary prevention among pregnant women
is less clear. Although iron-deficiency anemia during pregnancy is associated with
preterm delivery and delivering a low-birthweight baby (38 ), well designed, random-
ized control trials are needed to evaluate the effectiveness of universal iron
supplementation on mitigating adverse birth outcomes. Some studies have indicated
that adequate iron supplementation during pregnancy reduces the prevalence of iron-
deficiency anemia (6,10,39–42,66,104 ), but over the last few decades, the recom-
mendation by the Council on Foods and Nutrition and other groups to supplement
iron intake during pregnancy has not resulted in a reduced prevalence of anemia
among low-income, pregnant women (4,9,105 ). Evidence on iron supplement use is
limited, however, so it is not known how well the recommendation has been followed.
Conclusive evidence of the benefits of universal iron supplementation for all women
is lacking, but CDC advocates universal iron supplementation for pregnant women
because a large proportion of women have difficulty maintaining iron stores during
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pregnancy and are at risk for anemia (6,18,63 ), iron-deficiency anemia during preg-
nancy is associated with adverse outcomes (38 ), and supplementation during
pregnancy is not associated with important health risks (10,65,66 ).
Potential Adverse Effects of Increasing Dietary Iron Intake
Approximately 3.3 million women of childbearing age and 240,000 children aged
1–2 years have iron-deficiency anemia (45 ); conversely, up to one million persons in
the United States may be affected by iron overload due to hemochromatosis
(106,107 ) . Hemochromatosis is a genetic condition characterized by excessive iron
absorption, excess tissue iron stores, and potential tissue injury. If undetected and
untreated, iron overload may eventually result in the onset of morbidity (e.g., cirrho-
sis, hepatomas, diabetes, cardiomyopathy, arthritis or athropathy, or hypopituitarism
with hypogonadism), usually between ages 40 and 60 years. Clinical expression of
iron overload depends on the severity of the metabolic defect, the presence of suffi-
cient quantities of absorbable iron in the diet, and physiological blood loss from the
body (e.g., menstruation) (16 ). Transferrin saturation is the recommended screening
test for hemochromatosis; a repeated high value indicates hemochromatosis (108 ).
Preventing or treating the clinical signs of hemochromatosis involves repeated phle-
botomy to remove excess iron from the body (108 ).
Although increases in iron intake would seem contraindicated in persons with
hemochromatosis, there is no evidence that iron fortification of foods or the use of a
recommended iron supplementation regimen during pregnancy is associated with in-
creased risk for clinical disease due to hemochromatosis (16 ). Even when their dietary
intake of iron is approximately average, persons with iron overload due to hemochro-
matosis will require phlebotomy to reduce their body’s iron stores (108 ).
Secondary Prevention
Secondary prevention involves screening for, diagnosing, and treating iron defi-
ciency. Screening tests can be for anemia or for earlier indicators of iron deficiency
(e.g., erythrocyte protoporphyrin concentration or serum ferritin concentration). The
cost, feasibility, and variability of measurements other than Hb concentration and Hct
currently preclude their use for screening. The decision to screen an entire population
or to screen only persons at known risk for iron deficiency should be based on the
prevalence of iron deficiency in that population (73 ).
The percentage of anemic persons who are truly iron deficient (i.e., the positive
predictive value of anemia screening for iron deficiency) increases with increasing
prevalence of iron deficiency in the population (73 ). In the United States, children
from low-income families, children living at or below the poverty level, and black or
Mexican-American children are at higher risk for iron deficiency than are children from
middle- or high-income families, children living above the poverty level, and white
children, respectively (2,3,45 ). Routine screening for anemia among populations of
children at higher risk for iron deficiency is effective, because anemia is predictive of
iron deficiency. In populations having a low prevalence of anemia or a prevalence of
iron deficiency <10% (e.g., children from middle- or high-income families and white
children) (2,3,45 ), anemia is less predictive of iron deficiency (73 ), and selectively
screening only the persons having known risk factors for iron deficiency increases the
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positive predictive value of anemia screening (3,70 ). Because the iron stores of a full-
term infant of normal or high birthweight can meet the body’s iron requirements up to
age 6 months (23 ), anemia screening is of little value before age 6 months for these
infants.
Anemia among pregnant women and anemia among all nonpregnant women of
childbearing age should be considered together, because childbearing increases the
risk for iron deficiency (both during and after pregnancy) (41,42 ), and iron deficiency
before pregnancy likely increases the risk for iron deficiency during pregnancy (109 ).
Periodic screening for anemia among adolescent girls and women of childbearing age
is indicated for several reasons. First, most women have dietary intake of iron below
the recommended dietary allowance (46,47 ). Second, heavy menstrual blood loss,
which increases iron requirements to above the recommended dietary allowance, af-
fects an estimated 10% of women of childbearing age (17,18 ). Finally, the relatively
high prevalence of iron deficiency and iron-deficiency anemia among nonpregnant
women of childbearing age (45 ) and of anemia among low-income, pregnant women
(4 ) suggests that periodic screening for anemia is indicated among adolescent girls
and nonpregnant women of childbearing age during routine medical examinations
(73 ) and among pregnant women at the first prenatal visit. Among men and post-
menopausal women, in whom iron deficiency and iron-deficiency anemia are
uncommon (45 ), anemia screening is not highly predictive of iron deficiency.
RECOMMENDATIONS
Infants (Persons Aged 0–12 Months) and Preschool Children
(Persons Aged 1–5 Years)
Primary prevention of iron deficiency in infants and preschool children should be
achieved through diet. Information on diet and feeding is available in the Pediatric
Nutrition Handbook (8 ), Guide to Clinical Preventive Services (10 ), Nutrition and Your
Health: Dietary Guidelines for Americans (14 ), Breastfeeding and the Use of Human
Milk (110 ), and Clinician’s Handbook of Preventive Services: Put Prevention into Prac-
tice (111 ). For secondary prevention of iron deficiency in this age group, screening for,
diagnosing, and treating iron-deficiency anemia are recommended.
Primary Prevention
Milk and Infant Formulas
• Encourage breast feeding of infants.
• Encourage exclusive breast feeding of infants (without supplementary liquid, for-
mula, or food) for 4–6 months after birth.
• When exclusive breast feeding is stopped, encourage use of an additional source
of iron (approximately 1 mg/kg per day of iron), preferably from supplementary
foods.
• For infants aged <12 months who are not breast fed or who are partially breast
fed, recommend only iron-fortified infant formula as a substitute for breast milk.
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• For breast-fed infants who receive insufficient iron from supplementary foods by
age 6 months (i.e., <1 mg/kg per day), suggest 1 mg/kg per day of iron drops.
• For breast-fed infants who were preterm or had a low birthweight, recommend
2–4 mg/kg per day of iron drops (to a maximum of 15 mg/day) starting at 1 month
after birth and continuing until 12 months after birth.
• Encourage use of only breast milk or iron-fortified infant formula for any milk-
based part of the diet (e.g., in infant cereal) and discourage use of low-iron milks
(e.g., cow’s milk, goat’s milk, and soy milk) until age 12 months.
• Suggest that children aged 1–5 years consume no more than 24 oz of cow’s milk,
goat’s milk, or soy milk each day.
Solid Foods
• At age 4–6 months or when the extrusion reflex disappears, recommend that
infants be introduced to plain, iron-fortified infant cereal. Two or more servings
per day of iron-fortified infant cereal can meet an infant’s requirement for iron at
this age.
• By approximately age 6 months, encourage one feeding per day of foods rich in
vitamin C (e.g., fruits, vegetables, or juice) to improve iron absorption, preferably
with meals.
• Suggest introducing plain, pureed meats after age 6 months or when the infant
is developmentally ready to consume such food.
Secondary Prevention
Universal Screening
• In populations of infants and preschool children at high risk for iron-deficiency
anemia (e.g., children from low-income families, children eligible for the Special
Supplemental Nutrition Program for Women, Infants, and Children [WIC], mi-
grant children, or recently arrived refugee children), screen all children for
anemia between ages 9 and 12 months, 6 months later, and annually from ages
2 to 5 years.
Selective Screening
• In populations of infants and preschool children not at high risk for iron-defi-
ciency anemia, screen only those children who have known risk factors for the
condition. These children are described in the next three bulleted items.
• Consider anemia screening before age 6 months for preterm infants and low-
birthweight infants who are not fed iron-fortified infant formula.
• Annually assess children aged 2–5 years for risk factors for iron-deficiency ane-
mia (e.g., a low-iron diet, limited access to food because of poverty or neglect, or
special health-care needs). Screen these children if they have any of these risk
factors.
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• At ages 9–12 months and 6 months later (at ages 15–18 months), assess infants
and young children for risk factors for anemia. Screen the following children:
— Preterm or low-birthweight infants
— Infants fed a diet of non-iron-fortified infant formula for >2 months
— Infants introduced to cow’s milk before age 12 months
— Breast-fed infants who do not consume a diet adequate in iron after age 6
months (i.e., who receive insufficient iron from supplementary foods)
— Children who consume >24 oz daily of cow’s milk
— Children who have special health-care needs (e.g., children who use medi-
cations that interfere with iron absorption and children who have chronic
infection, inflammatory disorders, restricted diets, or extensive blood loss
from a wound, an accident, or surgery).
Diagnosis and Treatment
• Check a positive anemia screening result by performing a repeat Hb concentra-
tion or Hct test. If the tests agree and the child is not ill, a presumptive diagnosis
of iron-deficiency anemia can be made and treatment begun.
• Treat presumptive iron-deficiency anemia by prescribing 3 mg/kg per day of iron
drops to be administered between meals. Counsel the parents or guardians
about adequate diet to correct the underlying problem of low iron intake.
• Repeat the anemia screening in 4 weeks. An increase in Hb concentration of
≥1 g/dL or in Hct of ≥3% confirms the diagnosis of iron-deficiency anemia. If iron-
deficiency anemia is confirmed, reinforce dietary counseling, continue iron
treatment for 2 more months, then recheck Hb concentration or Hct. Reassess Hb
concentration or Hct approximately 6 months after successful treatment is com-
pleted.
• If after 4 weeks the anemia does not respond to iron treatment despite compli-
ance with the iron supplementation regimen and the absence of acute illness,
further evaluate the anemia by using other laboratory tests, including MCV, RDW,
and serum ferritin concentration. For example, a serum ferritin concentration of
≤15 µg/L confirms iron deficiency, and a concentration of >15 µg/L suggests that
iron deficiency is not the cause of the anemia.
School-Age Children (Persons Aged 5–<12 Years) and
Adolescent Boys (Males Aged 12–<18 Years)
Among school-age children and adolescent boys, only those who have a history of
iron-deficiency anemia, special health-care needs, or low iron intake should be
screened for anemia. Age-specific anemia criteria should be used (Table 6). Treatment
for iron-deficiency anemia includes one 60-mg iron tablet each day for school-age chil-
dren and two 60-mg iron tablets each day for adolescent boys and counseling about
dietary intake of iron. Follow-up and laboratory evaluation are the same for school-
age children and adolescent boys as they are for infants and preschool children.
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Adolescent Girls (Females 12–<18 Years) and Nonpregnant
Women of Childbearing Age
Primary prevention of iron deficiency for adolescent girls and nonpregnant women
of childbearing age is through diet. Information about healthy diets, including good
sources of iron, is available in Nutrition and Your Health: Dietary Guidelines for Ameri-
cans (14 ). Screening for, diagnosing, and treating iron-deficiency anemia are
secondary prevention approaches. Age-specific anemia criteria should be used during
screening (Table 6).
Primary Prevention
• Most adolescent girls and women do not require iron supplements, but encour-
age them to eat iron-rich foods and foods that enhance iron absorption.
• Women who have low-iron diets are at additional risk for iron-deficiency anemia;
guide these women in optimizing their dietary iron intake.
Secondary Prevention
Screening
• Starting in adolescence, screen all nonpregnant women for anemia every 5–10
years throughout their childbearing years during routine health examinations.
• Annually screen for anemia women having risk factors for iron deficiency (e.g.,
extensive menstrual or other blood loss, low iron intake, or a previous diagnosis
of iron-deficiency anemia).
Diagnosis and Treatment
• Confirm a positive anemia screening result by performing a repeat Hb concentra-
tion or Hct test. If the adolescent girl or woman is not ill, a presumptive diagnosis
of iron-deficiency anemia can be made and treatment begun.
• Treat adolescent girls and women who have anemia by prescribing an oral dose
of 60–120 mg/day of iron. Counsel these patients about correcting iron deficiency
through diet.
• Follow up adolescent girls and nonpregnant women of childbearing age as is
done for infants and preschool children, except that for a confirmed case of iron-
deficiency anemia, continue iron treatment for 2–3 more months.
• If after 4 weeks the anemia does not respond to iron treatment despite compli-
ance with the iron supplementation regimen and the absence of acute illness,
further evaluate the anemia by using other laboratory tests, including MCV, RDW,
and serum ferritin concentration. In women of African, Mediterranean, or South-
east Asian ancestry, mild anemia unresponsive to iron therapy may be due to
thalassemia minor or sickle cell trait.
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Pregnant Women
Primary prevention of iron deficiency during pregnancy includes adequate dietary
iron intake and iron supplementation. Information about healthy diets, including good
sources of iron, is found in Nutrition and Your Health: Dietary Guidelines for Ameri-
cans (14 ). More detailed information for pregnant women is found in Nutrition During
Pregnancy and Lactation: An Implementation Guide (112 ). Secondary prevention in-
volves screening for, diagnosing, and treating iron-deficiency anemia.
Primary Prevention
• Start oral, low-dose (30 mg/day) supplements of iron at the first prenatal visit.
• Encourage pregnant women to eat iron-rich foods and foods that enhance iron
absorption.
• Pregnant women whose diets are low in iron are at additional risk for iron-defi-
ciency anemia; guide these women in optimizing their dietary iron intake.
Secondary Prevention
Screening
• Screen for anemia at the first prenatal care visit. Use the anemia criteria for the
specific stage of pregnancy (Table 6).
Diagnosis and Treatment
• Confirm a positive anemia screening result by performing a repeat Hb concentra-
tion or Hct test. If the pregnant woman is not ill, a presumptive diagnosis of
iron-deficiency anemia can be made and treatment begun.
• If Hb concentration is <9.0 g/dL or Hct is <27.0%, refer the patient to a physician
familiar with anemia during pregnancy for further medical evaluation.
• Treat anemia by prescribing an oral dose of 60–120 mg/day of iron. Counsel preg-
nant women about correcting iron-deficiency anemia through diet.
• If after 4 weeks the anemia does not respond to iron treatment (the woman re-
mains anemic for her stage of pregnancy and Hb concentration does not increase
by 1 g/dL or Hct by 3%) despite compliance with an iron supplementation regi-
men and the absence of acute illness, further evaluate the anemia by using other
tests, including MCV, RDW, and serum ferritin concentration. In women of Afri-
can, Mediterranean, or Southeast Asian ancestry, mild anemia unresponsive to
iron therapy may be due to thalassemia minor or sickle cell trait.
• When Hb concentration or Hct becomes normal for the stage of gestation, de-
crease the dose of iron to 30 mg/day.
• During the second or third trimester, if Hb concentration is >15.0 g/dL or Hct is
>45.0%, evaluate the woman for potential pregnancy complications related to
poor blood volume expansion.
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Postpartum Women
Women at risk for anemia at 4–6 weeks postpartum should be screened for anemia
by using a Hb concentration or Hct test. The anemia criteria for nonpregnant women
should be used (Table 6). Risk factors include anemia continued through the third tri-
mester, excessive blood loss during delivery, and a multiple birth. Treatment and
follow-up for iron-deficiency anemia in postpartum women are the same as for non-
pregnant women. If no risk factors for anemia are present, supplemental iron should
be stopped at delivery.
Men (Males Aged ≥18 Years) and Postmenopausal Women
No routine screening for iron deficiency is recommended for men or postmeno-
pausal women. Iron deficiency or anemia detected during routine medical examina-
tions should be fully evaluated for its cause. Men and postmenopausal women usually
do not need iron supplements.
CONCLUSION
In the United States, iron deficiency affects 7.8 million adolescent girls and women
of childbearing age and 700,000 children aged 1–2 years (45 ). Primary health-care
providers can help prevent and control iron deficiency by counseling individuals and
families about sound iron nutrition during infancy and beyond and about iron supple-
mentation during pregnancy, by screening persons on the basis of their risk for iron
deficiency, and by treating and following up persons with presumptive iron deficiency.
Implementing these recommendations will help reduce manifestations of iron defi-
ciency (e.g., preterm births, low birthweight, and delays in infant and child develop-
ment) and thus improve public health.
References
1. Yip R, Walsh KM, Goldfarb MG, Binkin NJ. Declining prevalence of anemia in childhood in
a middle-class setting: a pediatric success story? Pediatrics 1987;80(3):330–4.
2. Yip R, Binkin NJ, Fleshood L, Trowbridge FL. Declining prevalence of anemia among low-
income children in the United States. JAMA 1987;258(12):1619–23.
3. Yip R. The changing characteristics of childhood iron nutritional status in the United States.
In: Filer LJ Jr, ed. Dietary iron: birth to two years. New York, NY: Raven Press, 1989:37–61.
4. Perry GS, Yip R, Zyrkowski C. Nutritional risk factors among low-income pregnant US women:
the Centers for Disease Control and Prevention (CDC) Pregnancy Nutrition Surveillance Sys-
tem, 1979 through 1993. Semin Perinatol 1995;19(3):211–21.
5. Earl R, Woteki CE, eds. Iron deficiency anemia: recommended guidelines for the prevention,
detection, and management among U.S. children and women of childbearing age. Wash-
ington, DC: National Academy Press, 1993.
6. Allen LH. Pregnancy and iron deficiency: unresolved issues. Nutr Rev 1997;55(44):91–101.
7. Institute of Medicine. Nutrition during pregnancy. Washington, DC: National Academy Press,
1990.
8. Barness LA, ed. Pediatric nutrition handbook. 3rd ed. Elk Grove Village, IL: American Academy
of Pediatrics, 1993.
9. Hauth John C, Merenstein BB, eds. Guidelines for perinatal care. 4th ed. Elk Grove Village,
IL: American Academy of Pediatrics and American College of Obstetricians and Gynecologists,
1997.
10. U.S. Preventive Services Task Force. Screening for iron deficiency anemia—including iron
prophylaxis. In: Guide to clinical preventive services. 2nd ed. Alexandria, VA: International
Medical Publishing, 1996:231–46.
Vol. 47 / No. RR-3 MMWR 25
11. International Federation of Gynecology and Obstetrics. Nutrition during pregnancy. Int J Gyne-
col Obstet 1993;43:67–74. (ACOG Technical Bulletin no. 179.)
12. Anderson SA, ed. Guidelines for the assessment and management of iron deficiency in women
of childbearing age. Bethesda, MD: U.S. Department of Health and Human Services, Food
and Drug Administration, Center for Food Safety and Applied Nutrition, 1991.
13. Public Health Service. Caring for our future: the content of prenatal care. A report of the Public
Health Service Expert Panel on the Content of Prenatal Care. Washington, DC: U.S. Department
of Health and Human Services, Public Health Service, 1989.
14. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Nutrition
and your health: dietary guidelines for Americans. 4th ed. Washington, DC: U.S. Department
of Agriculture and U.S. Department of Health and Human Services, 1995. (Home and Garden
Bulletin no. 232.)
15. Public Health Service. Healthy people 2000: national health promotion and disease prevention
objectives. Washington, DC: U.S. Department of Health and Human Services, Public Health
Service, 1991. DHHS publication no. (PHS) 91-50212.
16. Bothwell TH. Overview and mechanisms of iron regulation. Nutr Rev 1995;53(9):237–45.
17. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron metabolism in man. Oxford, UK: Blackwell
Scientific Publications, 1979.
18. Bothwell TH, Charlton RW. Iron deficiency in women. Washington, DC: The Nutrition Foun-
dation, 1981.
19. Hallberg L. Bioavailability of dietary iron in man. Annu Rev Nutr 1981;1:123–47.
20. Skikne B, Baynes RD. Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW,
eds. Iron metabolism in health and disease. London, UK: W.B. Saunders, 1994:151–87.
21. Finch CA, Cook JD. Iron deficiency. Am J Clin Nutr 1984;39:471–7.
22. Siegenberg D, Baynes RD, Bothwell TH, et al. Ascorbic acid prevents the dose-dependent
inhibitory effects of polyphenols and phytates on nonheme-iron absorption. Am J Clin Nutr
1994;53:537–41.
23. Dallman PR, Siimes MA, Stekel A. Iron deficiency in infancy and childhood. Am J Clin Nutr
1980;33:86–118.
24. Green R, Charlton R, Seftel H, et al. Body iron excretion in man: a collaborative study. Am
J Med 1968;45:336–53.
25. Hallberg L. Iron balance in pregnancy. In: Berger H, ed. Vitamins and minerals in pregnancy
and lactation. New York, NY: Raven Press, 1988:115–27.
26. Kappus KD, Lundgren RG Jr, Juranek DD, Roberts JM, Spencer HC. Intestinal parasitism in
the United States: update on a continuing problem. Am J Trop Med Hyg 1994;50(6):705–13.
27. Stoltzfus RJ, Chwaya HM, Tielsch JM, Schulze KJ, Albonico M, Savioli L. Epidemiology of
iron deficiency anemia in Zanzibari schoolchildren: the importance of hookworms. Am J Clin
Nutr 1997;65:153–9.
28. Dallman PR, Looker AC, Johnson CL, Carroll M. Influence of age on laboratory criteria for
the diagnosis of iron deficiency anemia and iron deficiency in infants and children. In: Hallberg
L, Asp NG, eds. Iron nutrition in health and disease. London, UK: John Libby & Co., 1996:65–74.
29. DeMaeyer EM. Preventing and controlling iron deficiency anaemia through primary health
care: a guide for health administrators and programme managers. Geneva, Switzerland: World
Health Organization, 1989.
30. Herbert V. Everyone should be tested for iron disorders. J Am Diet Assoc 1992;92(12):1502–9.
31. Baynes RD. Iron deficiency. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron me-
tabolism in health and disease. London, UK: W.B. Saunders, 1994:189–225.
32. Pollitt E. Iron deficiency and cognitive function. Annu Rev Nutr 1993;13:521–37.
33. Idjradinata P, Pollitt E. Reversal of developmental delays in iron-deficient anaemic infants
treated with iron. Lancet 1993;341(8836):1–4.
34. Lozoff B, Jimenez E, Wolf AW. Long-term developmental outcome of infants with iron defi-
ciency. N Engl J Med 1991;325(10):687–94.
35. Goyer RA. Nutrition and metal toxicity. Am J Clin Nutr 1995;61(suppl):646S–650S.
36. Li R, Chen X, Yan H, Deurenberg P, Garby L, Hautvast JG. Functional consequences of iron
supplementation in iron deficient female cotton mill workers in Beijing, China. Am J Clin Nutr
1994;59(4):908–13.
26 MMWR April 3, 1998
37. Cook JD, Skikne BS, Baynes RD. Iron deficiency: the global perspective. In: Hershko C, Konijn
AN, Aisen P, eds. Progress in iron research. New York, NY: Plenum Press, 1994:219–28.
38. Scholl TO, Hediger ML, Fischer RL, Shearer JW. Anemia vs iron deficiency: increased risk
of preterm delivery in a prospective study. Am J Clin Nutr 1992;55:985–8.
39. Svanberg B, Arvidsson B, Norrby A, Rybo G, Sölvell L. Absorption of supplemental iron during
pregnancy: a longitudinal study with repeated bone-marrow studies and absorption meas-
urements. Acta Obstet Gynecol Scand Suppl 1975;48:87–108.
40. Sjöstedt JE, Manner P, Nummi S, Ekenved G. Oral iron prophylaxis during pregnancy: a com-
parative study on different dosage regimens. Acta Obstet Gynecol Scand Suppl 1977;60:3–9.
41. Puolakka J, Jänne O, Pakarinen A, Järvinen A, Vihko R. Serum ferritin as a measure of iron
stores during and after normal pregnancy with and without iron supplements. Acta Obstet
Gynecol Scand Suppl 1980;95:43–51.
42. Taylor DJ, Mallen C, McDougall N, Lind T. Effect of iron supplementation on serum ferritin
levels during and after pregnancy. Br J Obstet Gynaecol 1982;89:1011–7.
43. Hemminki E, Rimpelä U. A randomized comparison of routine versus selective iron supple-
mentation during pregnancy. J Am Coll Nutr 1991;10(1):3–10.
44. Hemminki E, Meriläinen J. Long-term follow-up of mothers and their infants in a randomized
trial on iron prophylaxis during pregnancy. Am J Obstet Gynecol 1995;173(1):205–9.
45. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency
in the United States. JAMA 1997;277(12):973–6.
46. National Research Council. Recommended dietary allowances. 10th ed. Washington, DC: Na-
tional Academy Press, 1989.
47. U.S. Department of Agriculture, Agricultural Research Service. Data tables: results from
USDA’s 1994–96 Continuing Survey of Food Intakes by Individuals and 1994–96 Diet and Health
Knowledge Survey [online]. Riverdale, MD: U.S. Department of Agriculture, Agricultural Re-
search Service, Beltsville Human Nutrition Research Center, December 1997. Available at:
http://www.barc.usda.gov/bhnrc/foodsurvey/home.htm. Accessed January 14, 1998.
48. Pizarro F, Yip R, Dallman PR, Olivares M, Hertrampf E, Walter T. Iron status with different
infant feeding regimens: relevance to screening and prevention of iron deficiency. J Pediatr
1991;118:687–92.
49. Walter T, Dallman PR, Pizarro F, et al. Effectiveness of iron-fortified infant cereal in prevention
of iron deficiency anemia. Pediatrics 1993;91(5):976–82.
50. Pisacane A, De Vizia B, Valiente A, et al. Iron status in breast-fed infants. J Pediatr 1995;
127(3):429–31.
51. Oski FA. Iron deficiency in infancy and childhood. N Engl J Med 1993;329(3):190–3.
52. Boutry M, Needlman R. Use of diet history in the screening of iron deficiency. Pediatrics
1996;98(6):1138–42.
53. Sawaya WN, Khalil JK, Al-Shalhat AF. Mineral and vitamin content of goat’s milk. J Am Diet
Assoc 1984;84(4):433–5.
54. USDA Nutrient Database for Standard Reference [database online]. Riverdale, MD: United
States Department of Agriculture, Agricultural Research Service, Beltsville Human Research
Center, September 1996. Available at: http://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl. Ac-
cessed January 16, 1998.
55. Yip R. Iron deficiency: contemporary scientific issues and international programmatic ap-
proaches. J Nutr 1994;124:1479S–1490S.
56. Oski FA. Iron-fortified formulas and gastrointestinal symptons in infants: a controlled study.
Pediatrics 1980;66(2):168–70.
57. Nelson SE, Ziegler EE, Copeland AM, Edwards BB, Fomon SJ. Lack of adverse reactions to
iron-fortified formula. Pediatrics 1988;81(3):360–4.
58. Scariati PD, Grummer-Strawn LM, Fein SB, Yip R. Risk of diarrhea related to iron content of
infant formula: lack of evidence to support the use of low-iron formula as a supplement for
breastfed infants. Pediatrics [serial online]. March 1997;99(3). Available at: http://www.pedi-
atrics.org/cgi/content/full/99/3/e2.
59. American Academy of Pediatrics Committee on Nutrition. Iron-fortified infant formulas. Pe-
diatrics 1989;84(6):1114–5.
60. Yip R, Dallman PR. Iron. In: Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition. 7th
ed. Washington, DC: International Life Sciences Institute Press, 1996:277–92.
Vol. 47 / No. RR-3 MMWR 27
61. Hallberg L. Iron requirements: comments on methods and some crucial concepts in iron nu-
trition. Biol Trace Elem Res 1992:35:25–45.
62. Mooij PNM, Thomas CMG, Doesburg WH, Eskes TKAB. The effects of oral contraceptives
and multivitamin supplementation on serum ferritin and hematological parameters. Int J Clin
Pharmacol Ther Toxicol 1992;30(2):57–62.
63. Thomsen JK, Prien-Larsen JC, Devantier A, Fogh-Andersen N. Low dose iron supplementation
does not cover the need for iron during pregnancy. Acta Obstet Gynecol Scand 1993;72:93–8.
64. Yu SM, Keppel KG, Singh GK, Kessel W. Preconceptional and prenatal multivitamin-mineral
supplement use in the 1988 National Maternal and Infant Health Survey. Am J Public Health
1996;86(2):240–2.
65. Galloway R, McGuire J. Determinants of compliance with iron supplementation: supplies,
side effects, or psychology? Soc Sci Med 1994;39(3):381–90.
66. Chanarin I, Rothman D. Further observations on the relation between iron and folate status
in pregnancy. Br Med J 1971;2:81–4.
67. Hemminki E, Uski A, Koponen P, Rimpelä U. Iron supplementation during pregnancy—expe-
riences of a randomized trial relying on health service personnel. Controlled Clin Trials
1989;10:290–8.
68. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency
anemia. N Engl J Med 1993;329(23):1691–5.
69. Yip R, Dallman PR. The roles of inflammation and iron deficiency as causes of anemia. Am
J Clin Nutr 1988;48:1295–300.
70. Yip R. Iron nutritional status defined. In: Filer LJ Jr, ed. Dietary iron: birth to two years. New
York, NY: Raven Press, 1989:19–36.
71. Tietz NW, ed. Clinical guide to laboratory tests. 3rd ed. Philadelphia, PA: W.B. Saunders, 1995.
72. CDC. CDC criteria for anemia in children and childbearing-aged women. MMWR 1989;
38(22):400–4.
73. Binkin NJ, Yip R. When is anemia screening of value in detecting iron deficiency? In: Hercberg
S, Galan P, Dupin H, eds. Recent knowledge on iron and folate deficiencies in the world. Vol.
197. Paris, France: L’Institut National de la Santé et de la Recherche Médicale, 1990:137–45.
74. Margolis HS, Hardison HH, Bender TR, Dallman PR. Iron deficiency in children: the relationship
between pretreatment laboratory tests and subsequent hemoglobin response to iron therapy.
Am J Clin Nutr 1981;34(10):2158–68.
75. Steer P, Alam MA, Wadsworth J, Welch A. Relation between maternal haemoglobin concen-
tration and birth weight in different ethnic groups. Br Med J 1995;310:489–91.
76. Lu ZM, Goldenberg RL, Cliver SP, Cutter G, Blankson M. The relationship between maternal
hematocrit and pregnancy outcome. Obstet Gynecol 1991;77:190–4.
77. Garn SM, Ridella SA, Petzold AS, Falkner F. Maternal hematologic levels and pregnancy out-
comes. Semin Perinatol 1981;5(2):155–62.
78. Murphy JF, O’Riordan J, Newcomb RG, Coles EC, Pearson JF. Relation of haemoglobin levels
in first and second trimesters to outcome of pregnancy. Lancet 1986;1(8488):992–5.
79. Dirren H, Logman MHGM, Barclay DV, Freire WB. Altitude correction for hemoglobin. Eur J
Clin Nutr 1994;48:625–32.
80. Nordenberg D, Yip R, Binkin NJ. The effect of cigarette smoking on hemoglobin levels and
anemia screening. JAMA 1990;264(12):1556–9.
81. Dallman PR, Barr GD, Allen CM, Shinefield HR. Hemoglobin concentration in white, black,
and Oriental children: is there a need for separate criteria in screening for anemia? Am J
Clin Nutr 1978;31:377–80.
82. Yip R, Schwartz S, Deinard AS. Hematocrit values in white, black, and American Indian children
with comparable iron status: evidence to support uniform diagnostic criteria for anemia among
all races. Am J Dis Child 1984;138:824–7.
83. Johnson-Spear MA, Yip R. Hemoglobin difference between black and white women with com-
parable iron status: justification for race-specific anemia criteria. Am J Clin Nutr 1994;
60:117–21.
84. Perry GS, Byers T, Yip R, Margen S. Iron nutrition does not account for the hemoglobin dif-
ferences between blacks and whites. J Nutr 1992;122:1417–24.
85. Bridges N, Parvin RM, van Assendelft OW. Evaluation of a new system for hemoglobin meas-
urement. Am Clin Products Rev 1987;6(4):22–25.
28 MMWR April 3, 1998
86. Bartfield JM. Robinson D, Lekas J. Accuracy of microcentrifuged hematocrits in the emergency
department. J Emerg Med 1993;11:673–6.
87. Beaton GH, Corey PN, Steele C. Conceptual and methodological issues regarding the
epidemiology of iron deficiency and their implications for studies of the functional conse-
quences of iron deficiency. Am J Clin Nutr 1989;50:575–88.
88. Borel MJ, Smith SM, Derr J, Beard JL. Day-to-day variations in iron-status indices in healthy
men and women. Am J Clin Nutr 1991;54:729–35.
89. Thomas WJ, Collins TM. Comparison of venipuncture blood counts with microcapillary meas-
urements in screening for anemia in one-year-old infants. J Pediatr 1982;101(1):32–5.
90. Pilch SM, Senti FR, eds. Assessment of the iron nutritional status of the U.S. population based
on data collected in the second National Health and Nutrition Examination Survey, 1976–1980.
Bethesda, MD: Federation of American Societies for Experimental Biology, Life Sciences Re-
search Office, 1984.
91. Dallman PR, Yip R, Johnson C. Prevalence and causes of anemia in the United States, 1976
to 1980. Am J Clin Nutr 1984;39:437–45.
92. Piomelli S. The diagnostic utility of measurements of erythrocyte porphyrins. Hematol Oncol
Clin North Am 1987;1(3):419–30.
93. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg P-A, Hultén L. Screening for iron
deficiency: an analysis based on bone-marrow examinations and serum ferritin determina-
tions in a population sample of women. Br J Haematol 1993;85:787–98.
94. Gibson RS. Principles of nutritional assessment. New York, NY: Oxford University Press, 1990.
95. Oski FA, Brugnara C, Nathan DG. A diagnostic approach to the anemic patient. In: Nathan
DG, Orkin SH, eds. Nathan and Oski’s hematology of infancy and childhood. 5th ed. Phila-
delphia, PA: W.B. Saunders Co., 1998:375–84.
96. Novak RW. Red blood cell distribution width in pediatric microcytic anemias. Pediatrics
1987;80(2):251–4.
97. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron
stores. N Engl J Med 1974;290(22):1213–6.
98. Cook JD, Finch CA. Assessing iron status of a population. Am J Clin Nutr 1979;32:2115–9.
99. Cooper MJ, Zlotkin SH. Day-to-day variation of transferrin receptor and ferritin in healthy
men and women. Am J Clin Nutr 1996;64:738–42.
100. Hamilton LD, Gubler CJ, Cartwright GE, Wintrobe MM. Diurnal variation in the plasma iron
level of man. Proc Soc Exp Biol Med 1950;75(1):65–8.
101. Looker AC, Sempos CT, Liu K, Johnson CL, Gunter EW. Within person variance in biochemical
indicators of iron status: effects on prevalence estimates. Am J Clin Nutr 1990;52:541–7.
102. Brittenham GM. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R,
Benz EJ Jr, Shattil SJ, Furie B, Cohen HJ, eds. Hematology: basic principles and practice.
2nd ed. New York, NY: Churchill Livingstone, 1995:492–523.
103. Looker AC, Gunter EW, Johnson CL. Methods to assess iron status in various NHANES surveys.
Nutr Rev 1995;53(9):246–54.
104. Simmons WK, Cook JD, Bingham KC, et al. Evaluation of a gastric delivery system for iron
supplementation in pregnancy. Am J Clin Nutr 1993;58:622–6.
105. Council on Foods and Nutrition Committee on Iron Deficiency. Iron deficiency in the United
States. JAMA 1968;203(6):119–24.
106. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993;328(22):1616–20.
107. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: a unifying
analysis of published intervention trials. J Med Screening 1996;3:178–84.
108. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Hereditary hemochromatosis.
Clin Chim Acta 1996;245:139–200.
109. Viteri FE. Effective iron supplementation does not happen in isolation. Am J Clin Nutr
1997;65:889–90.
110. American Academy of Pediatrics Work Group on Breastfeeding. Breastfeeding and the use
of human milk. Pediatrics 1997;100(6):1035–9.
111. Public Health Service. Clinician’s handbook of preventive services: put prevention into practice.
Washington, DC: U.S. Department of Health and Human Services, Public Health Service, Office
of Disease Prevention and Health Promotion, 1994.
112. Institute of Medicine. Nutrition during pregnancy and lactation: an implementation guide.
Washington, DC: National Academy Press, 1992.
Vol. 47 / No. RR-3 MMWR 29
The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control
and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis
for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to
listserv@listserv.cdc.gov. The body content should read SUBscribe mmwr-toc. Electronic copy also is
available from CDC’s World-Wide Web server at http://www.cdc.gov/ or from CDC’s file transfer protocol
server at ftp.cdc.gov. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government
Printing Office, Washington, DC 20402; telephone (202) 512-1800.
Data in the weekly MMWR are provisional, based on weekly reports to CDC by state health departments.
The reporting week concludes at close of business on Friday; compiled data on a national basis are officially
released to the public on the following Friday. Address inquiries about the MMWR Series, including material
to be considered for publication, to: Editor, MMWR Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta,
GA 30333; telephone (888) 232-3228.
All material in the MMWR Series is in the public domain and may be used and reprinted without
permission; citation as to source, however, is appreciated.
✩U.S. Government Printing Office: 1998-633-228/67061 Region IV
MMWR
